A Breakthrough in Cancer Detection
Cut the uncertainty, not the patient. Introducing a truly non-invasive breakthrough in cancer detection. DermTech has developed a proprietary process to extract RNA from skin tissue samples collected non-invasively, using an adhesive patch.
Answers for Physicians
Answers for Patients
The Accuracy of Genomics
Ribonucleic acids (RNA) are generated within cells and both reflect and influence gene activity. RNA is ubiquitous on skin—but so are RNAses, enzymes that digest RNA and protect against infection with viral RNA. DermTech has developed a powerful platform technology to harvest RNA from skin for molecular analysis.
Non-Invasive Adhesive Skin Biopsy
The Adhesive Patch Skin Biopsy Kit is designed to reliably collect stratum corneum tissues of the skin from nearly all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair (e.g scalp).
Our Products and Services
Our assays measure gene expression in pigmented lesions and melanoma, non-melanoma skin cancers and inflammatory skin diseases.
We have developed a proprietary process to extract RNA from skin tissue samples collected non-invasively, using an adhesive patch. Our Adhesive Skin Biopsy Collection System is uniquely optimized to produce the highest quality and yield of RNA. Once the RNA has been extracted, we use the tools of molecular biology to assess the expression level of specific genes that are associated with various skin conditions.
Advances in genetic analysis are revolutionizing the practice of medicine, improving patient care, enabling early disease detection, and advancing the treatment of diseases. Novel assays, based on state of the art gene expression analyses, are being developed to improve disease detection and diagnosis across therapeutic areas. Below are some of our current collaborators:
The DermTech Newsroom is where you’ll find up-to-date information about the company, including our latest press releases, media coverage, events and our blog.
Recent Press Releases
DermTech Announces Publication of “Gene Expression Analysis Differentiates Melanomas from Spitz Nevi”
LA JOLLA, Calif., May 7, 2018 /PRNewswire/ — DermTech, Inc., the global leader in non-invasive molecular dermatology, announced the publication of “Gene Expression Analysis Differentiates Melanomas from Spitz Nevi” in the May edition of the Journal of Drugs in Dermatology.read more
Recent Media Coverage
Dr. John Dobak, CEO, DermTech joins BISTalk Radio to discuss how he has served as Founder and CEO of several venture backed life science companies. He currently serves as the CEO of DermTech, Inc, the global leader in molecular and precision dermatology.read more
Recent Blog Posts
Management of atypical pigmented lesions involves ruling-out melanoma via a visual assessment followed by surgical biopsy and histopathology. Ideally, when melanomas are identified, they are found at the earliest stages (Melanoma in Situ (MIS)/Stage 1a) when a high cure rate is possible by wide excision.read more